Evidence map›Paper›PMID 41603173›Full record

ReviewCurrent drug targets2026

Mechanistic Approach to Ferroptosis in Cancer and Neurological Diseases.

Pranay Wal, Abhijeet Singh Jadaun, Rakesh Verma, Renuka Jyothi S, Sunil Kumar Dwivedi, Kunal Sharad Surwade, Namra Aziz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pranay WalPSIT-Pranveer Singh Institute of Technology Pharmacy, NH-19, Kanpur, Uttar Pradesh, 209305, India.
Abhijeet Singh JadaunPSIT-Pranveer Singh Institute of Technology Pharmacy, NH-19, Kanpur, Uttar Pradesh, 209305, India.
Rakesh VermaDepartment of Pharmacology, Institute of Medical Science, BHU, Varanasi, 221005, India.
Renuka Jyothi SDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Sunil Kumar DwivediSri Aurobindo Institute of Pharmacy, Indore MP, India.
Kunal Sharad SurwadeKCT's R G Sapkal Institute of Pharmacy, Nashik, India.
Namra AzizPSIT-Pranveer Singh Institute of Technology Pharmacy, NH-19, Kanpur, Uttar Pradesh, 209305, India.ORCID 0000-0003-1774-1043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a form of oxidative, iron-dependent, non-apoptotic cell death characterized by the accumulation of lipid peroxides and the depletion of glutathione. Ferroptosis plays a significant role in human cancer and is essential in neurological disorders, including neurodegeneration, stroke, and neurotrauma. One of the key challenges in cancer research is how to effectively kill cancer cells while leaving healthy cells intact. Cancer cells often have defects in cell death executioner mechanisms, which is one of the main reasons for therapy resistance. To enable growth, cancer cells exhibit an increased iron demand compared with normal, non-cancer cells. This iron dependency can make cancer cells more vulnerable to iron-catalyzed necrosis, referred to as ferroptosis. It is a newly identified regulated form of cell death, which is thought to play a major role in neurodegenerative diseases. The mechanisms of ferroptosis in several neurological disorders are discussed in detail in this article. It also provides an overview of emerging medications that target ferroptosis in the treatment of neurological disorders. It also highlights the variations and connections between the different cell death pathways implicated in neurological disorders. Clarifying the function of ferroptosis in the brain will help us better understand the mechanisms behind neurological disorders and offer possible strategies for both acute and long-term neurological illness prevention and therapy. Consequently, we provide an overview and brief description of the main pathways involved in ferroptosis in this review, focusing on its regulation and its dual roles as a tumor suppressor and an oncogenic process in various human malignancies. The identification of FDA-approved drugs as ferroptosis inducers has raised high expectations for ferroptosis as a promising new approach to killing therapy-resistant cancers.

Indexed as

FerroptosisNeoplasmsNervous System DiseasesAnimalsAntineoplastic AgentsHumansIronNeurodegenerative DiseasesAntineoplastic AgentsIroncancerFerroptosisneurodegenerative disorderoxidative stressreactive oxygen speciestumorigenesis

Identifiers

PMID41603173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.